Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 64

Sort by

Sort Order Select

Journal Articles

Real Life Long-Term Survival Analysis in Patients with Chronic Myeloid Leukemia Treated with Tkis in Spain

Luis Felipe Casado Montero, Valentin Garcia Gutierrez, MD, Pilar Giraldo, MD PhD, Manuel Perez-Encinas, Raquel de Paz, Joaquin Martinez-Lopez, Guiomar Bautista, Santiago Osorio, Maria Jose Requena, Luis Palomera, MD PhD, Maria Jesús Peñarrubia, Carmen Calle, Jose Angel Hernandez-Rivas, Nuria García-Ormeña, Juan Luis Steegmann, MD PhD

Blood (2016) 128 (22): 3074.

https://doi.org/10.1182/blood.V128.22.3074.3074

Published: 2016

Journal Articles

Sustained Overall Survival Benefit with Lenalidomide Plus Dexamethasone Versus No Treatment in Patients with Smoldering Myeloma at High Risk of Progression to Myeloma: Long Term Analysis

Maria-Victoria Mateos, MD PhD, Miguel-T Hernandez, Pilar Giraldo, MD PhD, Javier De La Rubia, Felipe De Arriba, Lucia Lopez-Corral, Laura Rosiñol, Bruno Paiva, PhD, Luis Palomera, MD PhD, Joan Bargay, MD, Albert Oriol, Felipe Prosper, MD, Javier Lopez, Sr., MD PhD, Jose-María Arguiñano, Nuria Quintana, Jose Luis Garcia, Joan Bladé, Juan José Lahuerta, MD PhD, Jesus San Miguel, MD PhD

Blood (2016) 128 (22): 3308.

https://doi.org/10.1182/blood.V128.22.3308.3308

Published: 2016

Journal Articles

Safety and Efficacy of Ruxolitinib for the Final Enrollment of JUMP: An Open-Label, Multicenter, Single-Arm, Expanded-Access Study in Patients with Myelofibrosis (N = 2233)

Lynda Foltz, MD FRCP, Giuseppe A. Palumbo, MD, Bruno Martino, MD, Francesca Palandri, MD PhD, Haifa Kathrin Al-Ali, MD, Anna Marina Liberati, MD, Philipp D. Le Coutre, MD, Alessandro M. Vannucchi, MD, Carmen Garcia-Hernandez, MD, Renato Tavares, MD, Martin Griesshammer, MD, Vikas Gupta, MD, Pia Raanani, MD, Pilar Giraldo, MD PhD, Catherine Bouard, Julian Perez Ronco, MD MBA, Sadhvi Khanna, MS, Andrey Zaritskey, MD

Blood (2016) 128 (22): 3107.

https://doi.org/10.1182/blood.V128.22.3107.3107

Published: 2016

Journal Articles

The Overexpression of the Hsa-miR99b-5p/Let-7e Cluster Identifies High-Risk Myelodisplastic Patients. an IPSS-R Stratification Combined Model Approach

Marcio Andrade-Campos, MD PhD, Marta Andres-Coduras, PhD, Fernando Ramos, MD, Pilar Giraldo, MD PhD

Blood (2016) 128 (22): 1973.

https://doi.org/10.1182/blood.V128.22.1973.1973

Published: 2016

Journal Articles

90Y-Ibritumomab-Tiuxetan Consolidation in First-Line Complete Response Follicular Lymphoma Patients. Single Center Outcomes Analysis after Five Years Median Follow-up

Marcio Andrade-Campos, MD PhD, Natalia Espinosa-Lara, MD, Paola Lievano, MD PhD, Luis Lopez-Gomez, MD PhD, Teresa Baringo, MD, Pilar Giraldo, MD PhD

Blood (2016) 128 (22): 5323.

https://doi.org/10.1182/blood.V128.22.5323.5323

Published: 2016

Journal Articles

Incidence of Malignancies in Gaucher's Disease Patients. Data of Spanish Gaucher's Disease Registry

Marcio Andrade-Campos, MD PhD, Abelardo Barez, Soledad Noya, M Angeles Fernández-Galán, Jose Balanzat, MD, F García-Bragado, Angela Ibañez, Pilar Giraldo, MD PhD

Blood (2016) 128 (22): 4881.

https://doi.org/10.1182/blood.V128.22.4881.4881

Published: 2016

Journal Articles

Imatinib Suspension and Validation (ISAV) Study: Results at 24 Months

Blood (2015) 126 (23): 2775.

https://doi.org/10.1182/blood.V126.23.2775.2775

Published: 2015

Journal Articles

Low-Dose Dexamethasone Does Not Abrogate the Immunomodulatory Effects of Lenalidomide and Both Reactivate the Impaired Immune System of High-Risk Smoldering Multiple Myeloma Patients

Blood (2015) 126 (23): 2955.

https://doi.org/10.1182/blood.V126.23.2955.2955

Published: 2015

Journal Articles

Safety and Efficacy of Bosutinib in Fourth Line Therapy of Chronic Myeloid Leukemia Patients

Valentín García-Gutiérrez, Dragana Milojkovic, María Luisa Martín Mateos, Simone Claudiani, Concepcion Boque, PhD, Luis Felipe Casado, Gloria González, Antonio Jiménez, Alejandra Martinez Trillos, Isabel Mata Vázquez, Ángel Ramírez Payer, Alberto Álvarez Larran, Elena Amutio Díez, Abelardo Bárez García, MD, Guiomar Bautista Carrascosa, Sabela Bobillo Varela, Beatriz Cuevas Ruiz, Mª Ángeles Fernández Fernández, María del Carmen García Garay, Pilar Giraldo, MD PhD, Jose María Guinea de Castro, Natalia De Las Heras Rodríguez, MD, Nuria Hernanz Soler, Ana Iglesias Pérez, José Luis López Lorenzo, Josep Maria Martí Tutusaus, MD PhD, Rolando Omar Vallansot, Fernando Ortega Rivas, Jose Manuel Puerta, Maria Jose Ramírez Sánchez, Esperanza Romero Picos, Mario Andrés Romo Collada, Ana Rosell Mas, Silvana Saavedra Gerosa, Ana Sebrango Sadia, José Tallón Pérez, Sandra Valencia, Juan Luis Steegmann, MD

Blood (2015) 126 (23): 2786.

https://doi.org/10.1182/blood.V126.23.2786.2786

Published: 2015

Journal Articles

Safety and Efficacy of Ruxolitinib in an 1869-Patient Cohort of JUMP: An Open-Label, Multicenter, Single-Arm, Expanded-Access Study in Patients with Myelofibrosis

Renato Tavares, MD, Giuseppe A. Palumbo, MD, Philipp Le Coutre, MD, Francesca Palandri, MD PhD, Haifa Kathrin Al-Ali, MD, Bruno Martino, MD, Anna Marina Liberati, MD, Jose Grasa Ullrich, MD, Massimo Breccia, MD, David Brittain, MD, Lynda Foltz, MD FRCP, Martin Griesshammer, MD, Pia Raanani, MD, Vikas Gupta, MD FRCP, FRCPath, Pilar Giraldo, MD PhD, Jagannath Ghosh, Bayane Tannir, Julian Perez Ronco, MD MBA, Alessandro M. Vannucchi, MD

Blood (2015) 126 (23): 2799.

https://doi.org/10.1182/blood.V126.23.2799.2799

Published: 2015

Journal Articles

Genetic Characterization of Waldenstrom Macroglobulinemia By Next Generation Sequencing: An Analysis of Fouteen Genes in a Series of 61 Patients

Cristina Jimenez, BsC, Isabel Prieto-Conde, BsC, María García-Álvarez, BsC, María Carmen Chillón, BsC, PhD, Aránzazu García-Mateo, MD, Fernando Escalante, MD, Tomás González-López, MD, Pilar Giraldo, MD PhD, Alfonso Garcia de Coca, MD PhD, Miguel Alcoceba, Ana Balanzategui, BsC, Maria Eugenia Sarasquete, BsC, PhD, Luis Alberto Marin, BsC, PhD, Maria-Victoria Mateos, Enrique M Ocio, Marcos González, MD PhD, Jesus F San Miguel, MD PhD, Ramon Garcia-Sanz, MD PhD, Noemi Puig, MD PhD

Blood (2015) 126 (23): 2971.

https://doi.org/10.1182/blood.V126.23.2971.2971

Published: 2015

Journal Articles

Long Term Outcomes of ERT in Children with Gaucher Disease. Spanish Experience

Marcio M Andrade, MD, Pilar Alfonso, PhD, Pilar Irún, PhD, Javier Dalmau, MD, Jose Luis Barbera, MD, Horacio Cano, MD, María Angeles Fernandez-Galan, MD, Rafael Franco, MD, Inmaculada Garcia, MD, Angela IbaÃ±ez, MD, Francisco Lendinez, MD, Elena Martin-Hernandez, MD, Luis Antonio Sancho-Val, MD, Pablo Sanjurjo, MDPhD, Miguel Pocovi, Prof, Pilar Giraldo, MD PhD

Blood (2014) 124 (21): 4950.

https://doi.org/10.1182/blood.V124.21.4950.4950

Published: 2014

Journal Articles

Safety and Efficacy of Ruxolitinib in an Open-Label, Multicenter, Single-Arm, Expanded-Access Study in Patients with Myelofibrosis (MF): An 1144-Patient Update

Bruno Martino, Philipp le Coutre, MD, Martin Griesshammer, MD, Thomas Illmer, MD, Rudolf Schlag, Cornelius F. Waller, MD, Anna Marina Liberati, Philippe Schafhausen, MD, Renato S Tavares, MD, Alessandro M. Vannucchi, MD, Pilar Giraldo, MD PhD, Lynda M Foltz, MD FRCP, Pia Raanani, MD, Vikas Gupta, MD FRCP, FRCPath, Bayane Tannir, Julian Perez Ronco, MD, Jaggannath Ghosh, Haifa Kathrin Al-Ali, MD

Blood (2014) 124 (21): 3197.

https://doi.org/10.1182/blood.V124.21.3197.3197

Published: 2014

Journal Articles

Long Term Follow-up on the Tretament of High Risk Smoldering Myeloma with Lenalidomide Plus Low Dose Dex (Rd) (phase III spanish trial): Persistent Benefit in Overall Survival

Maria-Victoria Mateos, MD PhD, Miguel T Hernandez, MD, Pilar Giraldo, MD PhD, Javier De La Rubia, Felipe de Arriba, Lucía López-Corral, MD PhD, Laura Rosiñol, MD PhD, Bruno Paiva, PhD, Luis Palomera, Joan Bargay, MD, Albert Oriol, MD, Felipe Prosper, MD, Javier López, Eduardo Olavarría, MD, Nuria Quintana, Jose Luis García, Joan Blade, Juan José Lahuerta, MD PhD, Jesus F. San Miguel

Blood (2014) 124 (21): 3465.

https://doi.org/10.1182/blood.V124.21.3465.3465

Published: 2014

Journal Articles

Prospective, Observational Study to Assess the Safety of Rituximab(R) in Combination with Chemotherapy in Patients with Previously-Untreated or Relapsed or Refractory B Cell-Lineage Chronic Lymphocytic Leukaemia (B-CLL): Final Results

Pilar Giraldo, MD PhD, Andres Lopez, MD PhD, Eduardo Rios, MD, Felix Carbonell, MD PhD, Javier Lopez, Angel Ramírez, MD, Alicia Rodriguez, MD, Marta Gomez, MD, Ricardo Garcia, MD, Patricia Baltasar, MD, Maria Duran, MD, Raul Perez, MD, Maria Garcia, MD, José Antonio Márquez, Javier De la Serna, MD PhD

Blood (2014) 124 (21): 5666.

https://doi.org/10.1182/blood.V124.21.5666.5666

Published: 2014

Journal Articles

The Risk of Relapse in CML Patients Who Discontinued imatinib Can Be Predicted Based on Patients Age and the Results of dPCR Analysis

Blood (2014) 124 (21): 813.

https://doi.org/10.1182/blood.V124.21.813.813

Published: 2014

Journal Articles

Bosutinib Apears to be Safe, with Low Cross Intolerance, in Patients Treated in 4th Line. Results of the Spanish Compassionate Use Program

Blood (2014) 124 (21): 5523.

https://doi.org/10.1182/blood.V124.21.5523.5523

Published: 2014

Journal Articles

A Phase 1/2 Study Of The Safety and Activity Of Escalating Doses Of Lenalidomide Plus Rituximab For Patients With Refractory Or Relapsed Chronic Lymphocytic Leukemia (LLC-Lenar-08)

Jose Francisco Tomas, MD, PhD, Marcos González, MD, Pilar Giraldo, MD PhD, Mª José Terol, Jose Antonio Pérez Simón, MD, PhD, Raquel de Oña, MD

Blood (2013) 122 (21): 5304.

https://doi.org/10.1182/blood.V122.21.5304.5304

Published: 2013

Journal Articles

Prospective, Observational Study To Assess The Safety Of Rituximab In Combination With Chemotherapy In Patients With Previously-Untreated Or Relapsed Or Refractory B Cell-Lineage Chronic Lymphocytic Leukaemia (B-CLL): Preliminary Results

Andres Lopez, Eduardo Rios, MD, Javier De la Serna, MD, PhD, Felix Carbobnell, MD, Cristina Garcia Bernaldez, Isabel Gonzalez-Grande, Pilar Giraldo, MD PhD

Blood (2013) 122 (21): 5310.

https://doi.org/10.1182/blood.V122.21.5310.5310

Published: 2013

Journal Articles

Validation of Digital-PCR Analysis through Programmed imatinib Interruption in Q-RT-PCR Negative Chronic Myeloid Leukemia Patients

Blood (2013) 122 (21): 4040.

https://doi.org/10.1182/blood.V122.21.4040.4040

Published: 2013

NARROW

Real Life Long-Term Survival Analysis in Patients with Chronic Myeloid Leukemia Treated with Tkis in Spain

Sustained Overall Survival Benefit with Lenalidomide Plus Dexamethasone Versus No Treatment in Patients with Smoldering Myeloma at High Risk of Progression to Myeloma: Long Term Analysis

Safety and Efficacy of Ruxolitinib for the Final Enrollment of JUMP: An Open-Label, Multicenter, Single-Arm, Expanded-Access Study in Patients with Myelofibrosis (N = 2233)

The Overexpression of the Hsa-miR99b-5p/Let-7e Cluster Identifies High-Risk Myelodisplastic Patients. an IPSS-R Stratification Combined Model Approach

90Y-Ibritumomab-Tiuxetan Consolidation in First-Line Complete Response Follicular Lymphoma Patients. Single Center Outcomes Analysis after Five Years Median Follow-up

Incidence of Malignancies in Gaucher's Disease Patients. Data of Spanish Gaucher's Disease Registry

Imatinib Suspension and Validation (ISAV) Study: Results at 24 Months

Low-Dose Dexamethasone Does Not Abrogate the Immunomodulatory Effects of Lenalidomide and Both Reactivate the Impaired Immune System of High-Risk Smoldering Multiple Myeloma Patients

Safety and Efficacy of Bosutinib in Fourth Line Therapy of Chronic Myeloid Leukemia Patients

Safety and Efficacy of Ruxolitinib in an 1869-Patient Cohort of JUMP: An Open-Label, Multicenter, Single-Arm, Expanded-Access Study in Patients with Myelofibrosis

Genetic Characterization of Waldenstrom Macroglobulinemia By Next Generation Sequencing: An Analysis of Fouteen Genes in a Series of 61 Patients

Long Term Outcomes of ERT in Children with Gaucher Disease. Spanish Experience

Safety and Efficacy of Ruxolitinib in an Open-Label, Multicenter, Single-Arm, Expanded-Access Study in Patients with Myelofibrosis (MF): An 1144-Patient Update

Long Term Follow-up on the Tretament of High Risk Smoldering Myeloma with Lenalidomide Plus Low Dose Dex (Rd) (phase III spanish trial): Persistent Benefit in Overall Survival

Prospective, Observational Study to Assess the Safety of Rituximab(R) in Combination with Chemotherapy in Patients with Previously-Untreated or Relapsed or Refractory B Cell-Lineage Chronic Lymphocytic Leukaemia (B-CLL): Final Results

The Risk of Relapse in CML Patients Who Discontinued imatinib Can Be Predicted Based on Patients Age and the Results of dPCR Analysis

Bosutinib Apears to be Safe, with Low Cross Intolerance, in Patients Treated in 4th Line. Results of the Spanish Compassionate Use Program

A Phase 1/2 Study Of The Safety and Activity Of Escalating Doses Of Lenalidomide Plus Rituximab For Patients With Refractory Or Relapsed Chronic Lymphocytic Leukemia (LLC-Lenar-08)

Prospective, Observational Study To Assess The Safety Of Rituximab In Combination With Chemotherapy In Patients With Previously-Untreated Or Relapsed Or Refractory B Cell-Lineage Chronic Lymphocytic Leukaemia (B-CLL): Preliminary Results

Validation of Digital-PCR Analysis through Programmed imatinib Interruption in Q-RT-PCR Negative Chronic Myeloid Leukemia Patients

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only